$3,180,000 of BRISTOL-MYERS SQUIBB COMPANY lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act Discussions regarding H.R.1, One Big Beautiful Bill Act regarding bio-pharmaceutical provisions Biosimilars reimbursement issues H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.1968, lobbied for passage of the Continuing Resolution to include PBM reform Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act Issues related to the six protected classes of medicines under Medicare Part D, regarding all bio-pharmaceutical issues Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation Intellectual Property Reform concerning bio-pharmaceutical industry S.864, HELP Copays Act S.526, Pharmacy Benefit Manager Transparency Act of 2025 H.R.3285, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act Modernizing and Ensuring Equity Act H.R.3521, Clinical Trials Modernization Act Discussions regarding Continuing Resolution to include PBM reform, H.R.1968 International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues"
You can find more data on corporate lobbying on Quiver Quantitative.
BMY Congressional Stock Trading
Members of Congress have traded $BMY stock 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $BMY stock by members of Congress over the last 6 months:
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 08/14.
- REPRESENTATIVE VIRGINIA FOXX sold up to $15,000 on 06/24.
- REPRESENTATIVE JEFFERSON SHREVE sold up to $50,000 on 05/12.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
BMY Insider Trading Activity
BMY insiders have traded $BMY stock on the open market 4 times in the past 6 months. Of those trades, 1 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $BMY stock by insiders over the last 6 months:
- DAVID V ELKINS (EVP, Chief Financial Officer) sold 56,000 shares for an estimated $2,650,480
- SAMIT HIRAWAT (EVP,Chief Med.Offr.,Drug Dev.) purchased 4,250 shares for an estimated $202,215
- BARTIE WENDY SHORT (EVP, Corporate Affairs) sold 378 shares for an estimated $16,718
- BENJAMIN HICKEY (President, RayzeBio Org.) sold 97 shares for an estimated $3,701
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BMY Hedge Fund Activity
We have seen 937 institutional investors add shares of BMY stock to their portfolio, and 1,324 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN removed 11,266,654 shares (-66.0%) from their portfolio in Q2 2025, for an estimated $521,533,413
- BLACKROCK, INC. added 10,859,975 shares (+6.7%) to their portfolio in Q2 2025, for an estimated $502,708,242
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 10,195,775 shares (+16.8%) to their portfolio in Q2 2025, for an estimated $471,962,424
- QUBE RESEARCH & TECHNOLOGIES LTD added 9,752,683 shares (+inf%) to their portfolio in Q2 2025, for an estimated $451,451,696
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 9,171,098 shares (+428.5%) to their portfolio in Q2 2025, for an estimated $424,530,126
- GQG PARTNERS LLC removed 8,998,262 shares (-74.8%) from their portfolio in Q2 2025, for an estimated $416,529,547
- FEDERATED HERMES, INC. removed 7,793,300 shares (-99.5%) from their portfolio in Q2 2025, for an estimated $360,751,857
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BMY Price Targets
Multiple analysts have issued price targets for $BMY recently. We have seen 3 analysts offer price targets for $BMY in the last 6 months, with a median target of $47.0.
Here are some recent targets:
- Andrew Baum from Citigroup set a target price of $47.0 on 08/01/2025
- Terence Flynn from Morgan Stanley set a target price of $34.0 on 07/10/2025
- Mohit Bansal from Wells Fargo set a target price of $53.0 on 04/28/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
